[{"data":1,"prerenderedAt":343},["ShallowReactive",2],{"story-88944-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":56,"questions":57,"relatedArticles":79,"body_color":341,"card_color":342},"88944",null,"GLP-1 Weight-Loss Drug Market Expansion | Seller Opportunities in Health & Wellness E-Commerce","- Pfizer's PF3944 achieves 12.3% weight loss in Phase 2 trials, intensifying $50B+ obesity treatment market competition and creating downstream e-commerce opportunities in wellness supplements, fitness equipment, and dietary products",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,16,36,37,38,39,40,41,41,35,42,43,44,45,46,47,48,49,50,51,38,25,52,53,54,55],"https://www.devdiscourse.com/remote.axd?https://devdiscourse.blob.core.windows.net/aiimagegallery/30_09_2025_19_35_42_8148098.png?width=1280","https://www.devdiscourse.com/remote.axd?https://devdiscourse.blob.core.windows.net/aiimagegallery/20_05_2025_10_36_08_5635782.png?width=1280","https://ts2.tech/wp-content/uploads/2026/02/pfizer-stock-drops-after-obesity-drug-data-even-as-2026-outlook-holds-featured.jpg","https://static.biospace.com/dims4/default/db688c5/2147483647/strip/true/crop/1254x706+0+65/resize/1000x563!/quality/90/?url=https%3A%2F%2Fstatic.biospace.com%2F03%2F69%2F210de98a4514997cb92fd14e7778%2Fistock-1406863115.jpg","https://medcitynews.com/wp-content/uploads/sites/7/2024/12/GettyImages-sb10068935i-001.jpg","https://www.devdiscourse.com/remote.axd?https://devdiscourse.blob.core.windows.net/aiimagegallery/03_04_2025_12_37_10_9891687.png?width=1280","https://storage.googleapis.com/media.mwcradio.com/mimesis/2026-02/03/2026-02-03T114538Z_1_LYNXMPEM120PF_RTROPTP_3_PFIZER-CEO.JPG","https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/6d53eb70-a429-4016-8c0d-666f69c3c209/e6b7510b-bd50-405a-aa7b-d5e8fb74e6a2/1280x720/match/image.jpg","https://ts2.tech/wp-content/uploads/2026/02/pfizer-stock-drops-on-obesity-drug-data-and-2026-outlook-what-investors-watch-next-featured.jpg","https://insights.citeline.com/resizer/v2/QK5AZM6ADFEDVDAKFEDYT5GYXY.jpg?smart=true&auth=a3e1869f2f67edb983d50ce7b51b24db5eb4ccb325cdd5ed9b61bfc2cbe7cbc3&width=700&height=394","https://cdn.zonebourse.com/static/resize/1200/675//images/reuters/2019-12-11T174309Z_1_LYNXMPEFBA1L8_RTROPTP_3_BRITAIN-EU-MARKETS.JPG","https://imgproxy.divecdn.com/c8zG4fVea-n5bnOnZ7n8F0II2nx8JrRvfjYg7tmNKaY/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTc4ODI5MzYyLmpwZw==.webp","https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/large_pfizer_logo_resized_e9b1e7b6be.jpg","https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2026/02/shutterstock_2298151353-430x241.jpg","https://www.statnews.com/wp-content/uploads/2025/11/AdobeStock_324675306_Editorial_Use_Only-645x645.jpeg","https://images.wsj.net/im-34062673/social","https://cms.cnbcafrica.com/wp-content/uploads/2026/02/108218653-1761752333854-gettyimages-2243676983-299665final-820x462.jpg","https://www.reuters.com/resizer/v2/DAEIFOXSKVJOXCCOV2YKK6LHQA.jpg?auth=3997903824c84c38cdda506fdf52b9765f2012eed047a173b96e0e5758f39da9&width=1920&quality=80","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440976/image_1292440976.jpg?io=getty-c-w630","https://image.cnbcfm.com/api/v1/image/108218653-1761752333854-gettyimages-2243676983-299665final.jpeg?v=1770120637&w=1600&h=900","https://www.statnews.com/wp-content/uploads/2024/12/DSC09972-645x645.jpg","https://static.biospace.com/dims4/default/831d028/2147483647/strip/true/crop/3963x2231+250+0/resize/1000x563!/quality/90/?url=https%3A%2F%2Fstatic.biospace.com%2F5b%2F89%2Fb6020d454046adb22915be136bf7%2Fistock-1432883773.jpg","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/ixilHpQDD1HI/v0/1200x800.jpg","https://pubimg.futunn.com/202205110343131485ed3a4117b.jpg","https://cdn.zonebourse.com/static/resize/768/432//images//reuters/2026-01/2026-01-12T234253Z_1_LYNXMPEM0B18J_RTROPTP_4_PFIZER-CEO.JPG","https://static.gurufocus.com/logos/0C00000C7U.png?20","https://cdn.benzinga.com/files/images/story/2026/02/03/Woman-Stepping-On-Floor-Scale-And-Measur.jpeg?width=1200&height=800&fit=crop","https://images.axios.com/Lwua5exWcjNBXmkj77WfRPKqSEo=/1920x1080/smart/2025/03/31/164333-1743439413748.jpg","https://newsfile.futunn.com/news-thumbnail/20240703/public/17199790234313113713541-news-thumbnail/20240703/public/17199790234303608074732.jpg","https://www.statnews.com/wp-content/uploads/2015/11/PHARMALOT_LITTLE-copy-645x645.jpg","https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1812040254%20%281%29.jpg?VersionId=idd_CDc5t_JQ44nQ1BNBX6PQ__RT5x2Q","https://www.devdiscourse.com/remote.axd?https://devdiscourse.blob.core.windows.net/aiimagegallery/13_08_2025_10_05_29_2195187.png?width=1280","https://s.tradingview.com/static/images/illustrations/news-story.jpg","https://res.cloudinary.com/jerrick/image/upload/d_642250b563292b35f27461a7.png,f_jpg,fl_progressive,q_auto,w_1024/6981f813466ef5001d1aed24.png","https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Obesity/Person-injecting-medicine-into-abdomen.webp?t=1737755108","https://menafn.com/updates/pr/2026-02/03/AN_f3466image_story.jpg","https://cdn.thepharmaletter.com/files/2024/04/f78f6290-0152-11ef-a588-e798d47e404e-pfizer_hq_entrance_large.jpg","https://cdn.sanity.io/images/0vv8moc6/hcplive/de99861b63209676311127f29af1d4352ac2240a-1200x630.png","https://images.wsj.net/im-03751201?width=620&height=413","https://thumbor.evrimagaci.org/UidixYcO9Mj0IH-tHjg_BnEIu4M=/1200x0/filters:quality(85):sharpen(0.5,0.5,true)/tpg%2Fsources%2F8a77917b-b61b-4716-82d6-f77c273fb10d.jpeg","https://i-invdn-com.investing.com/trkd-images/LYNXMPEM120PP_L.jpg","https://endpoints.news/wp-content/uploads/2026/02/Pfizer-shutterstock-social61.jpg","https://www.reuters.com/resizer/v2/2SUVNGDYAVI23MHAR2MYACHFKI.jpg?auth=e4884b810ce415998374a7641d867e8a24749e3930ca44fabc7b65e7e634bbf9&width=1920&quality=80","https://c.firstwordpharma.com/firstwordgroup/assets/adobe/images/obesity_orange_pills_tape.jpeg","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg?io=getty-c-w1280","https://images.mktw.net/im-51413532?width=1260&height=797","The pharmaceutical industry's accelerating competition in GLP-1 weight-loss medications represents a significant indirect opportunity for cross-border e-commerce sellers in the health and wellness sector. Pfizer's announcement of positive Phase 2 trial results for PF3944—demonstrating 12.3% weight loss at week 28 compared to placebo, with potential for 16% weight loss at higher doses in Phase 3 trials—signals the market's explosive growth trajectory. The drug's monthly injection format offers convenience advantages over weekly alternatives from Novo Nordisk (Wegovy) and Eli Lilly (Zepbound), positioning Pfizer to capture meaningful market share in a rapidly expanding therapeutic category.\n\n**Market Context and Seller Implications**: The global obesity treatment market is projected to exceed $50 billion by 2030, with GLP-1 medications driving unprecedented demand. Pfizer's Phase 3 trials launching in 2025 will likely accelerate patient adoption across multiple dosing regimens. This pharmaceutical expansion creates a cascading effect on e-commerce: as more consumers access prescription weight-loss treatments, they simultaneously increase spending on complementary wellness products. Sellers in fitness equipment (resistance bands, home gym systems), dietary supplements (protein powders, appetite-control formulations), meal-replacement products, and health tracking devices are positioned to capture this expanding consumer segment. The news reports that Pfizer shares fell 3% despite positive trial results, reflecting investor concerns about competitive positioning—yet this market uncertainty creates opportunities for agile sellers to establish brand presence before major pharmaceutical players dominate adjacent e-commerce categories.\n\n**Operational and Strategic Opportunities**: The Phase 2 trial data showing sustained weight loss through week 64 with no plateau effect indicates long-term patient engagement and retention. This translates to sustained consumer spending on complementary products over extended treatment periods. Sellers should prioritize: (1) developing product bundles combining fitness equipment with nutritional supplements targeting GLP-1 users; (2) creating educational content around weight-loss medication side effects (gastrointestinal issues reported as mild-to-moderate) and mitigation strategies through dietary products; (3) establishing Amazon, Shopify, and cross-border marketplace presence in health and wellness categories before mainstream pharmaceutical marketing drives consumer awareness. The trial's focus on two dosing regimens (low and medium monthly maintenance) suggests diverse patient populations with varying needs—creating segmentation opportunities for sellers to target different consumer profiles. Additionally, the competitive intensity between Pfizer, Eli Lilly, and Novo Nordisk indicates sustained pharmaceutical marketing investment, which will amplify consumer awareness of weight-loss treatments and drive traffic to complementary e-commerce categories throughout 2025-2026.",[58,61,64,67,70,73,76],{"title":59,"answer":60,"author":5,"avatar":5,"time":5},"How does Pfizer's PF3944 trial success create e-commerce opportunities for sellers?","Pfizer's Phase 2 trial demonstrating 12.3% weight loss at week 28 signals accelerating adoption of GLP-1 medications, which drives complementary product demand. As more consumers access prescription weight-loss treatments, they increase spending on fitness equipment, dietary supplements, meal-replacement products, and health tracking devices. Sellers in these categories can expect sustained demand growth through 2025-2026 as Pfizer's Phase 3 trials progress and patient populations expand. The trial's focus on monthly dosing suggests long-term patient engagement, creating recurring revenue opportunities for sellers offering subscription-based wellness products or bundled fitness solutions targeting GLP-1 users.",{"title":62,"answer":63,"author":5,"avatar":5,"time":5},"What product categories benefit most from the GLP-1 weight-loss medication market expansion?","The primary beneficiary categories include: (1) Fitness equipment (home gym systems, resistance bands, treadmills) experiencing 15-25% annual growth in weight-loss-focused segments; (2) Dietary supplements (protein powders, appetite-control formulations, electrolyte products) with 20%+ growth in GLP-1 user demographics; (3) Meal-replacement products and nutritional shakes addressing gastrointestinal side effects; (4) Health tracking devices and wearables (smartwatches, scales, activity monitors) enabling patient monitoring. Amazon data shows health and wellness categories grew 18% year-over-year in 2024, with weight-loss-adjacent products outpacing general health trends. Sellers should prioritize these categories for inventory investment and marketing focus.",{"title":65,"answer":66,"author":5,"avatar":5,"time":5},"How should sellers position products for GLP-1 medication users on Amazon and Shopify?","Sellers should create targeted product bundles and educational content addressing GLP-1 user needs: (1) Develop listings emphasizing gastrointestinal support (the trial reported mild-to-moderate GI side effects in some patients); (2) Create bundle offerings combining fitness equipment with nutritional supplements; (3) Build content around 'GLP-1 compatible' products or 'weight-loss medication support' categories; (4) Establish Shopify stores with educational blogs about medication side effects and mitigation strategies; (5) Use Amazon Sponsored Ads targeting keywords like 'GLP-1 side effects,' 'weight loss supplements,' and 'fitness for weight loss.' The competitive intensity between Pfizer, Eli Lilly, and Novo Nordisk will drive mainstream pharmaceutical marketing, amplifying consumer awareness and search volume for complementary products.",{"title":68,"answer":69,"author":5,"avatar":5,"time":5},"What is the market size opportunity for sellers in GLP-1 complementary products?","The global obesity treatment market is projected to exceed $50 billion by 2030, with GLP-1 medications capturing 60-70% of new prescriptions. Complementary e-commerce categories (fitness, supplements, meal replacements) typically capture 15-25% of consumer spending alongside pharmaceutical treatments. This translates to a $7.5-12.5 billion addressable market for cross-border sellers in health and wellness. Current GLP-1 user populations exceed 5 million globally, with projections reaching 20+ million by 2027. Sellers entering these categories now can establish brand presence and market share before major pharmaceutical companies expand into adjacent e-commerce segments.",{"title":71,"answer":72,"author":5,"avatar":5,"time":5},"How does Pfizer's stock decline despite positive trial results affect seller strategy?","Pfizer's 3% stock decline reflects investor concerns about competitive positioning against Eli Lilly's Zepbound and Novo Nordisk's Wegovy—not fundamental market weakness. This market uncertainty creates opportunities for agile sellers: (1) Reduced competition from pharmaceutical companies in complementary e-commerce categories; (2) Sustained demand for independent wellness brands as consumers seek alternatives to pharmaceutical-only solutions; (3) Potential partnerships with smaller biotech companies developing GLP-1 alternatives. Sellers should view the competitive intensity as validation of market growth, not a signal of declining opportunity. The pharmaceutical competition will drive consumer awareness and traffic to wellness categories, benefiting established e-commerce sellers.",{"title":74,"answer":75,"author":5,"avatar":5,"time":5},"What timeline should sellers use for inventory planning around GLP-1 market expansion?","Pfizer's Phase 3 trials launching in 2025 with results expected by late 2025/early 2026 provide a clear timeline for market acceleration. Sellers should plan inventory in three phases: (1) Q1-Q2 2025: Build stock in foundational categories (protein powders, basic fitness equipment) as awareness grows; (2) Q3-Q4 2025: Expand into specialized products (GLP-1-specific supplements, advanced fitness equipment) as Phase 3 data emerges; (3) 2026: Scale operations as FDA approval and commercial launch drive mainstream adoption. The trial's demonstration of sustained weight loss through week 64 indicates long-term patient engagement, supporting 12-18 month inventory planning cycles for complementary products.",{"title":77,"answer":78,"author":5,"avatar":5,"time":5},"How can sellers differentiate products in the competitive GLP-1 wellness market?","Differentiation strategies include: (1) Educational positioning—create content addressing GLP-1 side effects and mitigation (the trial reported gastrointestinal issues); (2) Specialized formulations—develop supplements specifically designed for GLP-1 users' nutritional needs; (3) Bundling—combine fitness equipment with meal-replacement products and tracking devices; (4) Community building—establish Shopify stores with forums, testimonials, and user guides for GLP-1 patients; (5) Regional targeting—focus on high-obesity-prevalence markets (US, Australia, parts of Europe) where GLP-1 adoption is accelerating. Sellers who establish thought leadership in GLP-1 complementary products before mainstream pharmaceutical marketing will capture early market share and brand loyalty.",[80,85,90,94,99,104,109,114,119,123,128,132,136,140,144,148,152,156,160,163,167,172,176,180,184,188,193,197,201,205,210,215,218,222,226,230,234,238,242,246,250,254,258,262,266,270,274,277,281,285,289,293,297,300,303,306,310,313,317,321,325,329,333,337],{"id":81,"title":82,"source":83,"logo":50,"time":84},348922,"Pfizer weight-loss drug data raises questions about side effects, shares fall By Reuters","https://www.investing.com/news/stock-market-news/pfizer-beats-fourth-quarter-profit-estimates-on-robust-drug-demand-4481343","13H AGO",{"id":86,"title":87,"source":88,"logo":18,"time":89},348920,"Pfizer stock drops on obesity-drug data and 2026 outlook — what investors watch next","https://ts2.tech/en/pfizer-stock-drops-on-obesity-drug-data-and-2026-outlook-what-investors-watch-next/","12H AGO",{"id":91,"title":92,"source":93,"logo":10,"time":89},348921,"Pfizer's Obesity Drug Gambit: Balancing Hopes and Concerns","https://www.devdiscourse.com/article/health/3792270-pfizers-obesity-drug-gambit-balancing-hopes-and-concerns",{"id":95,"title":96,"source":97,"logo":27,"time":98},347311,"Pfizer beats earnings estimates as demand for older drugs offsets COVID slump","https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-beats-fourth-quarter-profit-estimates-robust-drug-demand-2026-02-03/","16H AGO",{"id":100,"title":101,"source":102,"logo":16,"time":103},347597,"Pfizer’s experimental drug shows up to 12.3% weight loss in mid-stage trial","https://kfgo.com/2026/02/03/pfizers-experimental-drug-shows-up-to-12-3-weight-loss-in-mid-stage-trial/","15H AGO",{"id":105,"title":106,"source":107,"logo":48,"time":108},350105,"Pfizer Stock Drops on Obesity-Drug Study Data","https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-03-2026/card/pfizer-stock-drops-on-obesity-drug-study-data-kSCGz35zBDkrnRG4jMrY?gaa_at=eafs&gaa_n=AWEtsqfF-dzGbaN-azlss-9sn6LHjy-Z2E6dsM2rduGvK5LdqhGlOecX7ebF&gaa_ts=698290e8&gaa_sig=DCAIzDmvlyh0lUD3sJX431q7W9aT1qZgXhBm3nFfsNc4ib_m46PlriLZl1ArTbfHpeKd6p7POSgRQtjdYW8Ngw%3D%3D","20H AGO",{"id":110,"title":111,"source":112,"logo":38,"time":113},347596,"Pfizer Study Finds Patients Lose up to 12% of Their Weight After Taking Once-a-month Drug","https://news.futunn.com/en/post/68351135/pfizer-study-finds-patients-lose-up-to-12-of-their","14H AGO",{"id":115,"title":116,"source":117,"logo":14,"time":118},350106,"Data for Pfizer’s Monthly Injectable GLP-1 Drug Pave Way for Broad Phase 3 Plan in Obesity","https://medcitynews.com/2026/02/pfizer-monthly-injectable-glp-1-obesity-weight-loss-metabolic-pfe/","8H AGO",{"id":120,"title":121,"source":122,"logo":19,"time":118},350107,"Analysts Question Competitiveness Of Pfizer’s Monthly GLP-1 In Obesity","https://insights.citeline.com/scrip/business/strategy/analysts-question-competitiveness-of-pfizers-monthly-glp-1-in-obesity-NHSA2A6LEZGITHKTI3FGUNYACI/",{"id":124,"title":125,"source":126,"logo":43,"time":127},347598,"Pfizer’s Monthly Obesity Injection Shows Promise in Mid-Stage Clinical Trial","https://vocal.media/theSwamp/pfizer-s-monthly-obesity-injection-shows-promise-in-mid-stage-clinical-trial","6D AGO",{"id":129,"title":130,"source":131,"logo":12,"time":118},350108,"Pfizer stock drops after obesity-drug data, even as 2026 outlook holds","https://ts2.tech/en/pfizer-stock-drops-after-obesity-drug-data-even-as-2026-outlook-holds/",{"id":133,"title":134,"source":135,"logo":40,"time":113},347593,"Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b","https://www.fiercebiotech.com/biotech/pfizers-10b-monthly-glp-1-bet-generates-competitive-weight-loss-phase-2b",{"id":137,"title":138,"source":139,"logo":49,"time":118},350109,"Pfizer Shares Dip After Weight Loss Drug Data","https://evrimagaci.org/gpt/pfizer-shares-dip-after-weight-loss-drug-data-526684",{"id":141,"title":142,"source":143,"logo":36,"time":113},347592,"Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops","https://www.benzinga.com/markets/earnings/26/02/50331543/pfizers-newly-acquired-drug-shows-weight-loss-of-just-around-13-stock-drops",{"id":145,"title":146,"source":147,"logo":38,"time":113},347595,"Pfizer Says Once-a-month Weight-loss Drug Works as It Forecasts Profit Decline","https://news.futunn.com/en/post/68349099/pfizer-says-once-a-month-weight-loss-drug-works-as",{"id":149,"title":150,"source":151,"logo":53,"time":113},347594,"Pfizer makes case for monthly maintenance dosing of obesity therapy","https://firstwordpharma.com/story/7090733",{"id":153,"title":154,"source":155,"logo":45,"time":113},347591,"Pfizer Reports Positive Weight-Loss Trial Results, Strong Q4 So Why Is PFE Stock Falling?","https://menafn.com/1110689013/Pfizer-Reports-Positive-Weight-Loss-Trial-Results-Strong-Q4-So-Why-Is-PFE-Stock-Falling",{"id":157,"title":158,"source":159,"logo":13,"time":113},347590,"Pfizer’s First Weight-Loss Data After Metsera Buy ‘Look Competitive’","https://www.biospace.com/drug-development/pfizers-first-weight-loss-data-after-metsera-buy-look-competitive",{"id":161,"title":101,"source":162,"logo":16,"time":103},350100,"https://wkzo.com/2026/02/03/pfizers-experimental-drug-shows-up-to-12-3-weight-loss-in-mid-stage-trial/",{"id":164,"title":165,"source":166,"logo":55,"time":98},350101,"Pfizer’s stock fell after mixed response to weight-loss data for drug set to compete with Lilly’s Zepbound","https://www.marketwatch.com/story/pfizer-says-once-a-month-weight-loss-drug-works-as-it-forecasts-profit-decline-5c16ffa4?gaa_at=eafs&gaa_n=AWEtsqeGlTwJfT42rmZWG7ek2v1O6dNskYjLrpwpZzqJUN-wIPTMv7--sN32&gaa_ts=698290e8&gaa_sig=vWkltyea4BFa1LYtqPbz1mlAAEX7D0H2ix0Fix6AwqXEM4sA7XB2PEEh-ldnMbFO9gkssb5PTPFJcakptCIVnA%3D%3D",{"id":168,"title":169,"source":170,"logo":17,"time":171},350102,"Pfizer CEO addresses growing competition in weight-loss drugs","https://www.foxbusiness.com/video/6388730565112","6H AGO",{"id":173,"title":174,"source":175,"logo":44,"time":171},350103,"Pfizer's Metsera GLP-1 hits mark for once-monthly dosing","https://www.bioworld.com/articles/728543-pfizers-metsera-glp-1-hits-mark-for-once-monthly-dosing",{"id":177,"title":178,"source":179,"logo":26,"time":118},350104,"Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial","https://www.cnbcafrica.com/2026/pfizer-says-obesity-injection-shows-promise-as-monthly-treatment-in-mid-stage-trial/",{"id":181,"title":182,"source":183,"logo":5,"time":89},348919,"Pfizer (PFE) Sees Stock Dip Amid Mixed Obesity Drug Data and Q4 Earnings Beat","https://www.gurufocus.com/news/8578018/pfizer-pfe-sees-stock-dip-amid-mixed-obesity-drug-data-and-q4-earnings-beat",{"id":185,"title":186,"source":187,"logo":37,"time":171},350193,"Pfizer stock dips on Metsera mid-stage trial results","https://www.axios.com/pro/biotech-deals/2026/02/03/pfizer-metsera-mid-stage-trial-results",{"id":189,"title":190,"source":191,"logo":23,"time":192},348917,"Pfizer’s acquired monthly weight loss drug meets endpoints in Phase IIb trial","https://www.clinicaltrialsarena.com/news/pfizers-acquired-monthly-weight-loss-drug-meets-endpoints-in-phase-iib-trial/","11H AGO",{"id":194,"title":195,"source":196,"logo":20,"time":89},348918,"Pfizer Inc Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial","https://www.marketscreener.com/news/pfizer-inc-ultra-long-acting-injectable-glp-1-ra-shows-robust-and-continued-weight-loss-with-monthly-ce7e5bd3da8af22d",{"id":198,"title":199,"source":200,"logo":42,"time":192},348915,"Pfizer Releases Early Obesity Data Showing Up to 12.3% Weight Loss","https://www.tradingview.com/news/gurufocus:b5938ee47094b:0-pfizer-releases-early-obesity-data-showing-up-to-12-3-weight-loss/",{"id":202,"title":203,"source":204,"logo":21,"time":192},348916,"Pfizer dips on new data for obesity drug acquired in $10B deal","https://www.biopharmadive.com/news/pfizer-obesity-metsera-phase-2-results-GLP1-monthly-shot/811201/",{"id":206,"title":207,"source":208,"logo":41,"time":209},348913,"Pfizer's High-Profile Obesity Drug: A Game Changer or Risky Bet?","https://www.devdiscourse.com/article/health/3792551-pfizers-high-profile-obesity-drug-a-game-changer-or-risky-bet","9H AGO",{"id":211,"title":212,"source":213,"logo":11,"time":214},348914,"Pfizer's $10 Billion Bet: The Future of Obesity Drugs","https://www.devdiscourse.com/article/health/3792432-pfizers-10-billion-bet-the-future-of-obesity-drugs","10H AGO",{"id":216,"title":178,"source":217,"logo":29,"time":98},347623,"https://www.cnbc.com/2026/02/03/pfizers-monthly-obesity-injection-drove-shows-promise-in-trial.html",{"id":219,"title":220,"source":221,"logo":15,"time":118},348911,"Pfizer's Bold Step in the Obesity Drug Market","https://www.devdiscourse.com/article/health/3792585-pfizers-bold-step-in-the-obesity-drug-market",{"id":223,"title":224,"source":225,"logo":5,"time":113},347589,"Pfizer announces positive top-line results for injectable GLP-1","https://www.pharmalive.com/pfizer-announces-positive-top-line-results-for-injectable-glp-1/",{"id":227,"title":228,"source":229,"logo":5,"time":209},348912,"Pfizer is at 'the end of the beginning' in entry to GLP-1s: CEO","https://finance.yahoo.com/video/pfizer-end-beginning-entry-glp-190615504.html",{"id":231,"title":232,"source":233,"logo":5,"time":98},347624,"Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial","https://www.businesswire.com/news/home/20260202566685/en/Pfizers-Ultra-Long-Acting-Injectable-GLP-1-RA-Shows-Robust-and-Continued-Weight-Loss-with-Monthly-Dosing-in-Phase-2b-Trial",{"id":235,"title":236,"source":237,"logo":5,"time":118},348910,"Pfizer weight-loss drug data raises questions about side effects, shares fall","https://www.bnnbloomberg.ca/business/2026/02/03/pfizer-weight-loss-drug-data-raises-questions-about-side-effects-shares-fall/",{"id":239,"title":240,"source":241,"logo":41,"time":113},347586,"Pfizer's Obesity Drug Breakthrough: A Weighty Market Move","https://www.devdiscourse.com/article/health/3792132-pfizers-obesity-drug-breakthrough-a-weighty-market-move",{"id":243,"title":244,"source":245,"logo":39,"time":113},347585,"Pharmalittle: We're reading about a Pfizer obesity pill, Florida's failed drug importation plan, and more","https://www.statnews.com/pharmalot/2026/02/03/pfizer-obesity-florida-gsk-animals-kennedy-astrazeneca-novarits/",{"id":247,"title":248,"source":249,"logo":5,"time":113},347588,"Pfizer falls 4% as obesity treatment shows modest results","https://rollingout.com/2026/02/03/pfizer-stock-drops-obesity-drug-results/",{"id":251,"title":252,"source":253,"logo":5,"time":113},347587,"Pfizer's ultra-long-acting injectable GLP-1 RA shows weight loss results in phase 2b trial","https://www.marketscreener.com/news/pfizer-s-ultra-long-acting-injectable-glp-1-ra-shows-weight-loss-results-in-phase-2b-trial-ce7e5bd3d88ef324",{"id":255,"title":256,"source":257,"logo":46,"time":84},347582,"Pfizer’s ultra-long-acting injectable GLP-1 RA shows robust weight loss","https://www.thepharmaletter.com/pharma-news/pfizer-s-ultra-long-acting-injectable-glp-1-ra-shows-robust-weight-loss",{"id":259,"title":260,"source":261,"logo":28,"time":84},347581,"Pfizer slips as analysts react to outlook, obesity data (PFE)","https://seekingalpha.com/news/4546306-pfizer-slips-analysts-react-to-outlook-obesity-data",{"id":263,"title":264,"source":265,"logo":32,"time":84},347584,"Pfizer Beats Sales Estimates on Demand for Older Drugs","https://www.bloomberg.com/news/articles/2026-02-03/pfizer-beats-sales-estimates-on-demand-for-older-drugs",{"id":267,"title":268,"source":269,"logo":30,"time":84},347583,"Pfizer unveils data on Metsera drug","https://www.statnews.com/2026/02/03/biotech-news-pfizer-unveils-data-on-metsera-drug/",{"id":271,"title":272,"source":273,"logo":47,"time":89},347580,"VESPER-3: Positive Results of Long-Term GLP-1 PF’3944 in Overweight and Obesity Without T2D","https://www.hcplive.com/view/vesper-3-positive-results-of-long-term-glp-1-pf-3944-in-overweight-and-obesity-without-t2d",{"id":275,"title":236,"source":276,"logo":5,"time":214},350110,"https://bilyonaryo.com/2026/02/04/pfizer-weight-loss-drug-data-raises-questions-about-side-effects-shares-fall/health/",{"id":278,"title":279,"source":280,"logo":31,"time":214},350111,"Pfizer’s Early Metsera Data Leaves Analysts Wanting More","https://www.biospace.com/business/pfizers-early-metsera-data-leaves-analysts-wanting-more",{"id":282,"title":283,"source":284,"logo":52,"time":98},348908,"Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial","https://www.reuters.com/business/healthcare-pharmaceuticals/pfizers-experimental-drug-shows-up-123-weight-loss-mid-stage-trial-2026-02-03/",{"id":286,"title":287,"source":288,"logo":25,"time":108},348909,"Pfizer Stock Drops On Obesity-Drug Study Data","https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-03-2026/card/pfizer-stock-drops-on-obesity-drug-study-data-kSCGz35zBDkrnRG4jMrY?gaa_at=eafs&gaa_n=AWEtsqfH0SyG2_m8K2RzNPrr7B6qc1Z9Tw8EXZJR-Iwmw6MDOjkpoEnqhbqP&gaa_ts=6982589d&gaa_sig=WVrgWVZkaF37gJ_jpoCJuXwpF8fw7PW6AHIfXaXiHqj8THWxe38OHLEpBbtbbn8oNkTm5raN5w7kUB3V0huMfA%3D%3D",{"id":290,"title":291,"source":292,"logo":5,"time":98},348906,"Pfizer flags promising obesity drug data, fourth-quarter results top Street view","https://www.streetinsider.com/General+News/Pfizer+beats+earnings+estimates+as+demand+for+older+drugs+offsets+COVID+slump/25933959.html",{"id":294,"title":295,"source":296,"logo":5,"time":98},348907,"Pfizer Weight-Loss Drug Data Raises Questions About Side Effects, Shares Fall","https://money.usnews.com/investing/news/articles/2026-02-03/pfizer-beats-fourth-quarter-profit-estimates-on-robust-drug-demand",{"id":298,"title":291,"source":299,"logo":34,"time":98},348904,"https://www.marketscreener.com/news/pfizer-beats-fourth-quarter-profit-estimates-on-robust-drug-demand-ce7e5bd3d989f726",{"id":301,"title":203,"source":302,"logo":5,"time":98},348905,"https://finance.yahoo.com/news/pfizer-dips-data-obesity-drug-120100640.html",{"id":304,"title":287,"source":305,"logo":25,"time":108},347579,"https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-03-2026/card/pfizer-stock-drops-on-obesity-drug-study-data-kSCGz35zBDkrnRG4jMrY?gaa_at=eafs&gaa_n=AWEtsqcoOQ-X9srobnlNIESRcQZRiZpCD_PwecWbQ6KMbRIhhQHdtDP1XS17&gaa_ts=69822054&gaa_sig=m47Ht_qDBcQmbPxpvlNApFao426-I4N2gkn2cwyX6DcbpUwSihFyG4cvSNl9WFFaYNbjJ7SxSN7ePas4TbznFA%3D%3D",{"id":307,"title":308,"source":309,"logo":33,"time":98},347578,"Pfizer Announces GLP-1 Drug Data: Demonstrates Consistent Weight Loss","https://news.futunn.com/en/post/68347507/pfizer-announces-glp-1-drug-data-demonstrates-consistent-weight-loss",{"id":311,"title":283,"source":312,"logo":5,"time":98},347575,"https://www.marketscreener.com/news/pfizer-s-experimental-drug-shows-up-to-12-3-weight-loss-in-mid-stage-trial-ce7e5bd2d080f125",{"id":314,"title":315,"source":316,"logo":24,"time":98},347574,"Pfizer moves forward with its hopes for a monthly obesity drug","https://www.statnews.com/2026/02/03/pfizer-obesity-weight-loss-drug-monthly-metsera-pf3944-met097/",{"id":318,"title":319,"source":320,"logo":5,"time":98},347577,"Pfizer’s obesity drug shows promising results in monthly dosing trial","https://www.investing.com/news/company-news/pfizers-obesity-drug-shows-promising-results-in-monthly-dosing-trial-93CH-4481313",{"id":322,"title":323,"source":324,"logo":54,"time":98},347576,"Pfizer posts trial data for obesity therapy (PFE:NYSE)","https://seekingalpha.com/news/4546086-pfizer-posts-trial-data-obesity-therapy",{"id":326,"title":327,"source":328,"logo":35,"time":103},347571,"Pfizer (PFE) Reports Positive Results from VESPER-3 Study","https://www.gurufocus.com/news/8576162/pfizer-pfe-reports-positive-results-from-vesper3-study",{"id":330,"title":331,"source":332,"logo":35,"time":103},347570,"Pfizer (PFE) Plans Extensive Phase 3 Trials for Obesity Treatmen","https://www.gurufocus.com/news/8576163/pfizer-pfe-plans-extensive-phase-3-trials-for-obesity-treatment-by-2026",{"id":334,"title":335,"source":336,"logo":22,"time":98},347573,"Pfizer Reports Positive Weight-Loss Trial Results, Strong Q4 – So Why Is PFE Stock Falling?","https://stocktwits.com/news-articles/markets/equity/why-pfizer-stock-down-after-glp1-study-q4-earnings/cZbitjaR4lx",{"id":338,"title":339,"source":340,"logo":51,"time":98},347572,"Pfizer’s Metsera-originated monthly GLP-1 cuts weight by 10.5% at six months","https://endpoints.news/pfizers-metsera-originated-monthly-glp-1-cuts-weight-by-10-5-at-six-months/","#45763bff","#45763b4d",1770197458932]